Posts found in:

Healthcare & Life Science

KO Client Watchmaker Genomics Raises $40M Series A Round Image

KO Client Watchmaker Genomics Raises $40M Series A Round

KO client Watchmaker Genomics, a life sciences company specializing in the development of high-stringency applications focused on the reading, writing and editing of DNA and RNA, has raised $40M to expand its clinical sequencing product offerings.   The KO team, led by partner Jon Taylor, of counsel Melissa Mellen and attorney…

Clinimark Acquired by Element Materials Technology Image

Clinimark Acquired by Element Materials Technology

KO client Clinimark, a global leader for clinical FDA validation testing of vital sign data for medical and home health devices, has been acquired by Element Materials Technology. The KO team, led by attorney Ryan Sykora, partner John Gaddis, attorney Logan DeSouza and corporate paralegal Sara Shelly, represented Clinimark in…

Highline Sciences Acquired by Tempus Image

Highline Sciences Acquired by Tempus

KO client Highline Sciences, a specialized, full-service clinical contract research organization (CRO) focused on oncology, has been acquired by Tempus. The KO team, led by attorneys Samantha Pjesky, Jon Taylor and Ryan Ivey, represented Highline in this acquisition. Tempus is a leader in artificial intelligence and precision medicine. With this…

KO Pharmacology Research and Drug Discovery Client Plato BioPharma, Inc. Acquired by Inotiv, Inc. Image

KO Pharmacology Research and Drug Discovery Client Plato BioPharma, Inc. Acquired by Inotiv, Inc.

KO Client Plato BioPharma, Inc., a Colorado-based pharmacology research and drug discovery company, has been acquired by leading contract research organization Inotiv, Inc. The KO team, led by partner John Gaddis, represented Plato BioPharma in the acquisition. Plato BioPharma specializes in cardiovascular, renal, pulmonary and hepatic therapeutic areas, specifically within…

KO Client Sydnexis Completes $45M Series B Financing Image

KO Client Sydnexis Completes $45M Series B Financing

Sydnexis, Inc., a clinical stage biopharmaceutical company, has completed a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund. The KO team, led by partners Kevin Gibson and Brad Schoenfeld, represented Sydnexis. The company sees progressive myopia (nearsightedness) in children as a “significant…

KO Client VitriVax Closes Series A Financing Round Image

KO Client VitriVax Closes Series A Financing Round

VitriVax, the developer of a novel stabilization and delivery platform for vaccines and therapeutics, has closed its first institutional financing round with Adjuvant Capital. KO partners Jon Taylor and Brad Schoenfeld, and attorney Matt Burns represented VitriVax in the financing round. The Series A proceeds will be used to develop…

Proactively Protecting Your Company’s Growth: The Early-Stage Guide to Using a Corporate Lawyer Image

Proactively Protecting Your Company’s Growth: The Early-Stage Guide to Using a Corporate Lawyer

When you have limited dollars for legal issues, it’s important to know where to spend those funds to maximize your company’s investment in legal resources without waste and inefficiency.​ Experienced corporate counsel will tell early stage companies in most industries to focus on two priorities as soon as possible: capital…

Addressing CRO Consolidation Risks: How to Protect Clinical Trials Image

Addressing CRO Consolidation Risks: How to Protect Clinical Trials

Contract Research Organization (CRO) consolidation has become a constant force in the life sciences market. This shifting environment has made protecting clinical trial success and anticipating and planning for CRO consolidation risks critical for pharmaceutical and medical device companies when negotiating agreements. Working with high-performing CROs, with deep industry and…